Infective vaginitis

disease
On this page

Also known as PV - Vaginal infectionVaginal infection

Summary

Infective vaginitis (MONDO:0023557) is a disease and 33 clinical trials. Top therapeutic interventions include dequalinium, doxycycline anhydrous, and terconazole. A subtype of vaginitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 33

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameinfective vaginitis
Mondo IDMONDO:0023557
ICD-111436361154
NCITC84353
SNOMED CT237091009
UMLSC0404521
MedGen140795
Is cancer (heuristic)no

Also known as: PV - Vaginal infection · Vaginal infection · vaginal infection

Disease family

This is a subtype of vaginitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorderfemale reproductive system disordervaginal disordervaginitisinfective vaginitis

Related subtypes (2): postmenopausal atrophic vaginitis, vulvovaginitis

Subtypes (4): bacterial vaginosis, vulvovaginal candidiasis, herpetic vulvovaginitis, trichomonal vulvovaginitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 33.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified19
PHASE37
PHASE43
PHASE23
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01697826PHASE4COMPLETEDComparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections
NCT03532464PHASE4COMPLETEDAzithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection
NCT05788991PHASE4TERMINATEDComparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis
NCT00694928PHASE3COMPLETEDVaginal Infection Study 2
NCT01152528PHASE3UNKNOWNVa-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery
NCT02308007PHASE3COMPLETEDMulti-Center Study of New Medications to Treat Vaginal Infections
NCT02308033PHASE3COMPLETEDMulti-Center Study of New Medications to Treat Vaginal Infections
NCT02308046PHASE3COMPLETEDMulti-Center Study of New Medications to Treat Vaginal Infections
NCT05021315PHASE3UNKNOWNVaginal Cleaning Using Povidone Iodine Before CS to Reduce Postoperative Wound Infection
NCT05590195PHASE3UNKNOWNEffect of PreforPro® on Urinary and Vaginal Health
NCT01055106PHASE2COMPLETEDDose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis
NCT01593124PHASE2COMPLETEDIdentification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation
NCT03372395PHASE2COMPLETEDProbiotic Implementation as Help in Solving Vaginal Infections
NCT01812889PHASE1COMPLETEDEvaluation of Intravaginal Gel and Ovule Formulations of TOL-463
NCT06530186Not specifiedNOT_YET_RECRUITINGEvaluation of a Postcoital Sponge on Self-Reported Vaginal Health Parameters
NCT00324246Not specifiedCOMPLETEDFeasibility Study of the NEW NORMA-SENSE
NCT00802763Not specifiedUNKNOWNPerformance Proof of the New NORMA-SENSE
NCT01542606Not specifiedWITHDRAWNPerformance Proof of Product Developed to Detect Abnormal Vaginal pH
NCT01599416Not specifiedCOMPLETEDInfluence of U-relax on Vaginal Health Promotion and HPV DNA Test Change From Positive to Negative
NCT01843166Not specifiedCOMPLETEDVaginal Estrogen With Pessary Treatment
NCT03008421Not specifiedCOMPLETEDOral Probiotics to Reduce Vaginal Group B Streptococcal Colonization in Late Pregnancy
NCT03050684Not specifiedCOMPLETEDDoes Vaginal Washing Affect the Success Rate of the Labour Induction?
NCT03261804Not specifiedCOMPLETEDRelation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users
NCT03898726Not specifiedCOMPLETEDLaparoscopic Versus Transvaginal Cuff Closure
NCT04461782Not specifiedCOMPLETEDInterventional Study to Evaluate the Effect of the Oral Administration of L.Plantarum on Vaginal Microbiota
NCT04719754Not specifiedUNKNOWNEpidemiology of Abnormal Vaginal Discharge During Pregnancy
NCT04725981Not specifiedTERMINATEDVaginal Stump Infection After Laparoscopic Hysterectomy
NCT05005286Not specifiedCOMPLETEDEvaluation of Breastmilk Microbiota as a Function for Immunity
NCT05044156Not specifiedCOMPLETEDInvestigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women
NCT05109533Not specifiedCOMPLETEDProbiotics Role in HPV Cervico-vaginal Infection Clearance
NCT05557318Not specifiedUNKNOWNUsing Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge
NCT05806879Not specifiedUNKNOWNImpact of Maternity Napkins on the Incidence of Vaginal Infections in the Post-partum Period
NCT05997160Not specifiedUNKNOWNResearch on Vaginal Microbiota Evaluation Unified Standards Based on Gram Staining

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
DEQUALINIUM43
DOXYCYCLINE ANHYDROUS43
TERCONAZOLE42
AZITHROMYCIN41
BUTOCONAZOLE NITRATE41
CLINDAMYCIN41
CLINDAMYCIN PHOSPHATE41
IMIQUIMOD41
NONOXYNOL 941
CHEMBL429938101
CHEMBL479131201
CHEMBL379276301